1 active not recruiting, 1 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Genotype: new trials by email Literature Review of Genotype trials Research Report on Genotype
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: Dichloroacetate (DCA), Placebo, Genotype - Pyruvate Dehydrogenase Complex Deficiency | Phase 3 | Active not recruiting | Saol Therapeutics Inc | 34 | 2020-07-14 | 2025-05-04 |
| Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder desvenlafaxine succinate sustained release, Genotyping - Depressive Disorder, Major | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 437 | 2009-02-01 | 2011-03-10 |
Depressive Disorder, Major (1) · Pyruvate Dehydrogenase Complex Deficiency Disease (1)
Saol Therapeutics Inc (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (1)
PMID 24571916, PMID 24583567, PMID 25012446, PMID 25758058, PMID 26644956, PMID 26709542, PMID 27009044, PMID 29140227, PMID 34183490